GLOBAL PROBENECID MARKET
INTRODUCTION
Probenecid, also sold under the brand name Probalan, is a medication that increases uric acid excretion in the urine. It is primarily used in treating gout and hyperuricemia. Probenecid was developed as an alternative to caronamide to competitively inhibit renal excretion of some drugs, thereby increasing their plasma concentration and prolonging their effects.
Probenecid is primarily used to treat gout and hyperuricemia. Probenecid is sometimes used to increase the concentration of some antibiotics and to protect the kidneys when given with cidofovir. Specifically, a small amount of evidence supports the use of intravenous cefazolin once rather than three times a day when it is combined with probenecid.
It has also found use as a masking agent, potentially helping athletes using performance-enhancing substances to avoid detection by drug tests.
Mild symptoms such as nausea, loss of appetite, dizziness, vomiting, headache, sore gums, or frequent urination are common with this medication. Life-threatening side effects such as thrombocytopenia, hemolytic anemia, leukemia and encephalopathy are extremely rare.
Theoretically probenecid can increase the risk of uric acid kidney stones. Some of the important clinical interactions of probenecid include those with captopril, indomethacin, ketoprofen, ketorolac, naproxen, cephalosporins, quinolones, penicillins, methotrexate, zidovudine, ganciclovir, lorazepam, and acyclovir.
In all these interactions, the excretion of these drugs is reduced due to probenecid, which in turn can lead to increased concentrations of these.
GLOBAL PROBENECID MARKET SIZE AND FORECAST
The Global Probenecid market accounted for $XX Billion in 2022 and is anticipated to reach $XX Billion by 2030, registering a CAGR of XX% from 2023 to 2030.
NEW PRODUCT LAUNCH
Glaxo Probenecid – PROBENECID belongs to a class of medication called uricosuric, primarily used to decrease blood uric acid levels in the body. It is used to treat Gout and Gouty arthritis (increased uric acid leading to inflammation).
Gout is a painful type of inflammatory arthritis. It normally affects one joint at a time (often the big toe joint). This condition is caused by high uric acid levels.
PROBENECID contains probenecid, which works by blocking urate tubular reabsorption, lowering serum urate levels. This prevents uric acid synthesis within the body without interfering with the necessary mechanisms of cells and the body.
PROBENECID is not recommended for use in children below two years of age. It is advised not to drive vehicles or operate machines as PROBENECID can make the patient drowsy.
COMPANY PROFILE
- Glaxo
- Gland
- Auro Pharma
- Pfizer
- Emcure pharma
THIS REPORT WILL ANSWER FOLLOWING QUESTIONS
- How many Probenecid are manufactured per annum globally? Who are the sub-component suppliers in different regions?
- Cost breakup of a Global Probenecid and key vendor selection criteria
- Where is the Probenecid manufactured? What is the average margin per unit?
- Market share of Global Probenecid market manufacturers and their upcoming products
- Cost advantage for OEMs who manufacture Global Probenecid in-house
- key predictions for next 5 years in Global Probenecid market
- Average B-2-B Probenecid market price in all segments
- Latest trends in Probenecid market, by every market segment
- The market size (both volume and value) of the Probenecid market in 2023-2030 and every year in between?
- Production breakup of Probenecid market, by suppliers and their OEM relationship
